Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney disease

FierceBiotechAvalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs

Thermo FisherThermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo Finance

AgilentDoes Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st

10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance

10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpace

Thermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking Alpha

MOONS'How Artemis will help the U.S. create a moon base - NBC News

AgilentAgilent Technologies Inc (A) Shares Fall 5.0% -- What GF Score o - GuruFocus

Thermo FisherThermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatch

FierceBiotechDespite data concerns, Roche’s oral SERD can still be largest product in company history: exec

FierceBiotechRegeneron ushers in new genetic medicine era with groundbreaking gene therapy approval

Thermo FisherThermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business Journals